{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:24Z","timestamp":1792652124236,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116065","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:04:46Z","timestamp":1708167886000},"page":"116065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax"],"prefix":"10.1016","volume":"228","author":[{"given":"Jianlei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcreyya","family":"Savasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-716X","authenticated-orcid":false,"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.bcp.2024.116065_b0010","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116065_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106317","article-title":"Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study","volume":"91","author":"Lou","year":"2020","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.bcp.2024.116065_b0020","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcp.2024.116065_b0025","doi-asserted-by":"crossref","first-page":"1149298","DOI":"10.3389\/fonc.2023.1149298","article-title":"Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia","volume":"13","author":"Sciume","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116065_b0030","doi-asserted-by":"crossref","first-page":"1137175","DOI":"10.3389\/fonc.2023.1137175","article-title":"Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116065_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071734","article-title":"Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: The PETHEMA registry experience","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers (basel)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14740\/wjon1557","article-title":"Real-world experience of adults with acute myeloid leukemia on hypomethylating agents with or without venetoclax at a comprehensive cancer center","volume":"14","author":"Freeman","year":"2023","journal-title":"World J Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116065_b0045","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2024.116065_b0050","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"The Lancet Haematology."},{"key":"10.1016\/j.bcp.2024.116065_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"7","key":"10.1016\/j.bcp.2024.116065_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076816","article-title":"Azacitidine is synergistically lethal with XPO1 inhibitor selinexor in acute myeloid leukemia by targeting XPO1\/eIF4E\/c-MYC signaling","volume":"24","author":"Long","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.bcp.2024.116065_b0070","first-page":"1262","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","volume":"106","author":"Li","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bcp.2024.116065_b0075","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bcp.2024.116065_b0080","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"37","key":"10.1016\/j.bcp.2024.116065_b0085","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2024.116065_b0090","first-page":"3893","article-title":"Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo","volume":"8","author":"Schwartz","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bcp.2024.116065_b0095","first-page":"13","article-title":"Detection of mycoplasma contaminations","volume":"290","author":"Uphoff","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116065_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"issue":"11\u201312","key":"10.1016\/j.bcp.2024.116065_b0105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","article-title":"c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia","volume":"27","author":"Liu","year":"2022","journal-title":"Apoptosis"},{"issue":"7","key":"10.1016\/j.bcp.2024.116065_b0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2024.116065_b0115","doi-asserted-by":"crossref","first-page":"41950","DOI":"10.1038\/srep41950","article-title":"Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.bcp.2024.116065_b0120","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.18632\/oncotarget.9185","article-title":"Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.bcp.2024.116065_b0125","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"43","key":"10.1016\/j.bcp.2024.116065_b0130","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.bcp.2024.116065_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.bcp.2024.116065_b0140","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.bcp.2024.116065_b0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.bcp.2024.116065_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115283","article-title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","volume":"205","author":"Hege Hurrish","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116065_b0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.bcp.2024.116065_b0160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2005-06-2219","article-title":"Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia","volume":"107","author":"Ge","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2024.116065_b0165","doi-asserted-by":"crossref","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.bcp.2024.116065_b0170","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2008-09-179812","article-title":"RUNX1 regulates phosphoinositide 3-kinase\/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia","volume":"114","author":"Edwards","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2024.116065_b0175","doi-asserted-by":"crossref","first-page":"e17138","DOI":"10.1371\/journal.pone.0017138","article-title":"Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells","volume":"6","author":"Xu","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2024.116065_b0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"4","key":"10.1016\/j.bcp.2024.116065_b0185","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.bcp.2024.116065_b0190","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","article-title":"Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies","volume":"23","author":"Rudek","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.bcp.2024.116065_b0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fendo.2018.00129","article-title":"The role for myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues","volume":"9","author":"Goetzman","year":"2018","journal-title":"Front Endocrinol (lausanne)."},{"issue":"5","key":"10.1016\/j.bcp.2024.116065_b0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2024.116065_b0210","article-title":"The roles of histone deacetylases and their inhibitors in cancer therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"21","key":"10.1016\/j.bcp.2024.116065_b0215","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1002\/cncr.33156","article-title":"Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia","volume":"126","author":"Karol","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0220","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2017.172411","article-title":"Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bcp.2024.116065_b0225","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2024.116065_b0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1593\/neo.81358","article-title":"Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment","volume":"11","author":"Yang","year":"2009","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.bcp.2024.116065_b0235","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bcp.2024.116065_b0240","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.bcp.2024.116065_b0245","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bcp.2024.116065_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106197","article-title":"Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia","volume":"85","author":"DeAngelo","year":"2019","journal-title":"Leuk. Res."},{"issue":"16","key":"10.1016\/j.bcp.2024.116065_b0255","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-19-0171","article-title":"Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results","volume":"25","author":"Wieduwilt","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2024.116065_b0260","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2024.116065_b0265","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Tan","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2024.116065_b0270","article-title":"A combined histone deacetylases targeting strategy to overcome venetoclax plus azacitidine regimen resistance in acute myeloid leukaemia: three case reports","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:14:45Z","timestamp":1731456885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":54,"alternative-id":["S0006295224000480"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116065","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116065"}}